scholarly journals Mortality of lung cancer as a second primary malignancy: A population‐based cohort study

2019 ◽  
Vol 8 (6) ◽  
pp. 3269-3277
Author(s):  
Lei Deng ◽  
Hrönn Harðardottír ◽  
Huan Song ◽  
Zhengrui Xiao ◽  
Changchuan Jiang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy

Prognosis of lung cancer as a second primary malignancy among cancer survivors: A population-based cohort study.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21005-e21005
Author(s):  
Lei Deng ◽  
Zhengrui Xiao ◽  
Changchuan Jiang ◽  
Qian Wang ◽  
Haiying Cheng ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Cancer Survivors ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy

The risk and prognosis of secondary primary malignancy in lung cancer: a population-based study

2021 ◽  
Author(s):  
Jia Hong ◽  
Rongrong Wei ◽  
Chuang Nie ◽  
Anastasiia Leonteva ◽  
Xu Han ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Cox Regression ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Risk Models ◽  
Primary Malignancy ◽  
Population Based Study ◽  
Competing Risk Models

Aim: To assess and predict risk and prognosis of lung cancer (LC) patients with second primary malignancy (SPM). Methods: LC patients diagnosed from 1992 to 2016 were obtained through the Surveillance, Epidemiology, and End Results database. Standardized incidence ratios were calculated to evaluate SPM risk. Cox regression and competing risk models were applied to assess the factors associated with overall survival, SPM development and LC-specific survival. Nomograms were built to predict SPM probability and overall survival. Results & conclusion: LC patients remain at higher risk of SPM even though the incidence declines. Patients with SPM have a better prognosis than patients without SPM. The consistency indexes for nomograms of SPM probability and overall survival are 0.605 (95% CI: 0.598–0.611) and 0.644 (95% CI: 0.638–0.650), respectively.

scholarly journals The risk of second primary malignancy in patients with stage Ia non-small cell lung cancer: a U.S. population-based study

2017 ◽  
Vol 57 (2) ◽  
pp. 239-243 ◽  
Author(s):  
Amit Khanal ◽  
Bilal Haider Lashari ◽  
Sreechandralekha Kruthiventi ◽  
Lubina Arjyal ◽  
Amir Bista ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Population Based ◽  
Small Cell ◽  
Second Primary ◽  
Small Cell Lung ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Population Based Study ◽  
Stage Ia

Risk of second primary malignancy in patients with sinonasal tumors: a population-based cohort study

2018 ◽  
Vol 8 (6) ◽  
pp. 756-762 ◽  
Author(s):  
Ashwin Ganti ◽  
Max A. Plitt ◽  
Edward C. Kuan ◽  
Hannah N. Kuhar ◽  
Pete S. Batra ◽  
...  
Keyword(s):  
Cohort Study ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy

Trends of Second Primary Malignancy in Patients with Thyroid Cancer: A Population-Based Cohort Study in Israel

Thyroid ◽  
2017 ◽  
Vol 27 (6) ◽  
pp. 793-801 ◽  
Author(s):  
Elena Izkhakov ◽  
Micha Barchana ◽  
Irena Liphshitz ◽  
Barbara G. Silverman ◽  
Naftali Stern ◽  
...  
Keyword(s):  
Cohort Study ◽  
Thyroid Cancer ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy
Sign in / Sign up

Export Citation Format

Share Document